DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Tirzepatide — sold as Zepbound and Mounjaro — is the first medicine to mimic two gut hormones at once. Here is the dual GIP/GLP‑1 mechanism, how it suppresses appetite and controls blood sugar, and why it outperforms single-hormone GLP‑1 drugs.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it mimics two "incretin" hormones your gut releases when you eat. Activating both receptors at once is what makes it distinct from every earlier weight-loss drug, which targeted only GLP-1.
The GLP-1 (glucagon-like peptide-1) action does four things: it slows how fast your stomach empties (so you stay full longer), signals satiety to appetite centers in the brain, prompts the pancreas to release insulin only when blood sugar is high (glucose-dependent, so low hypoglycemia risk), and suppresses glucagon (which otherwise raises blood sugar). This is the same pathway semaglutide uses.
GIP (glucose-dependent insulinotropic polypeptide) adds a second layer: more glucose-dependent insulin secretion and effects on how fat is stored and used, plus appetite signaling. Adding GIP activation on top of GLP-1 amplifies the appetite and metabolic benefit beyond what GLP-1 alone achieves.
Because it works two pathways, tirzepatide produces stronger results. In SURMOUNT-1 it reached about 21% average total body-weight loss, and in the head-to-head SURMOUNT-5 trial it beat semaglutide, 20.2% vs 13.7% at 72 weeks. It is a once-weekly injection, titrated up slowly from 2.5 mg to manage GI side effects, and is sold as Zepbound for weight management and Mounjaro for type 2 diabetes. Learn more on the tirzepatide overview, or see how semaglutide works for the single-hormone comparison.